Is Kyverna Therapeutics, Inc. (KYTX) a Buy, Sell, or Hold?
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$7.94 USD
$0.17 (2.19%)
- Volume
- 1.32M
- Average Volume
- 1.15M
- Market Capitalization
- $347.71M
- P/E Ratio
- -2.42
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $13.67
- Year Low
- $2.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.15
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Warner Biddle |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | KYTX |
| CUSIP | 501976104 |
| CIK | 0001994702 |
| Web | https://kyvernatx.com |
| Phone | (510) 925-2492 |
| Currency | USD |
| Employees | 130 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.17 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.15 |
| Quick Ratio | 8.15 |
| Cash Ratio | 1.08 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.50 |
| Price / Cash Flow | -2.30 |
| Price / Book | 2.45 |
Price Target and Rating
| Average Stock Price Forecast | $25.00 |
| High Stock Price Forecast | $25.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -68.24% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.64 |
| Trailing P/E Ratio | -2.42 |
| PEG Ratio | -2.92 |
| P/E Growth | -2.92 |
| Net Income | $-161.31M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -81.87% |
| Return on Assets | -60.85% |
Financials Score
| AltmanZ Score | -0.21 |
| Piotroski Score | 2.00 |
| Working Capital | 212.05M |
| Total Assets | 257.02M |
| Ebit | -155.27M |
| Market Cap | 340.26M |
| Total Liabilities | 61.44M |
Poll Results
About Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to K ... yverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Kyverna Therapeutics Sinks 13%: Here's Why
2026-07-10 15:59:59
Shares of Kyverna Therapeutics (NASDAQ:KYTX) are down almost 13% in Friday afternoon trading, changing hands near $8.60 after opening the session at $9.81.
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS
2026-07-06 07:15:59
Kyverna Therapeutics is positioned to pioneer the autoimmune CAR T space, leveraging miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. Recent regulatory alignment enables a rolling BLA submission for SPS, with pivotal single-arm Phase 2 data showing strong efficacy and safety, targeting FDA approval by late 2026. KYTX maintains a cash runway through 2028, supported by $236M in cash and a $150M credit facility, enabling completion of key trials and commercial launch preparation.
2026-06-22 08:00:00
EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026.
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
2026-06-08 14:34:25
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.
2026-06-03 08:00:00
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date 1 Data reinforce miv-cel's differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the presentation of updated data from the Phase 1 portion of COMPARE, a Phase 1/2 investigator-initiated trial (IIT) evaluating miv-cel (mivocabtagene autoleucel, KYV-101) in patients with active anti-citrullinated protein antibody (ACPA)-positive, treatment-refractory rheumatoid arthritis (RA).
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
2026-05-18 08:00:00
Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth Veteran biopharma leader joins to help lead Kyverna's next phase of commercial growth
Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-05-14 08:00:00
EMERYVILLE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that company management will present at the following upcoming conferences: H.C.
2026-05-12 16:02:00
Positive pre-BLA meeting with FDA alignment reached on KYSA-8 single-arm trial in stiff person syndrome (SPS); rolling BLA submission initiated
Frequently Asked Questions
-
What is the current Kyverna Therapeutics, Inc. (KYTX) stock price?
-
Kyverna Therapeutics, Inc.(NASDAQ:KYTX) stock price is $7.94 in the last trading session. During the trading session, KYTX stock reached the peak price of $13.67 while $2.8 was the lowest point it dropped to. The percentage change in KYTX stock occurred in the recent session was 2.19% while the dollar amount for the price change in KYTX stock was $0.17.
-
KYTX's industry and sector of operation?
-
The NASDAQ listed KYTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of KYTX?
-
Naji Gehchan | Chief Medical & Development Officer
Ritesh Srivastava | Chief Legal & Compliance Officer
Warner Biddle | Chief Executive Officer & Director
Dan Maziasz | Chief Business Officer
Cara Bauer | Chief Human Resources Officer -
How many employees does KYTX have?
-
Number of KYTX employees currently stands at 130. KYTX operates from 5980 Horton Street, Emeryville, CA 94608, US.
-
Link for KYTX official website?
-
Official Website of KYTX is: https://kyvernatx.com
-
How do I contact KYTX?
-
KYTX could be contacted at phone #(510) 925-2492 and can also be accessed through its website. KYTX operates from 5980 Horton Street, Emeryville, CA 94608, US.
-
How many shares of KYTX are traded daily?
-
The average number of KYTX shares traded daily for last 3 months was 1.15M.
-
What is the market cap of KYTX currently?
-
The market value of KYTX currently stands at $347.71M with its latest stock price at $7.94